for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Eris Lifesciences Ltd

ERIS.NS

Latest Trade

422.95INR

Change

0.40(+0.09%)

Volume

71,827

Today's Range

418.35

 - 

428.40

52 Week Range

358.10

 - 

746.00

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
422.55
Open
424.40
Volume
71,827
3M AVG Volume
2.73
Today's High
428.40
Today's Low
418.35
52 Week High
746.00
52 Week Low
358.10
Shares Out (MIL)
137.52
Market Cap (MIL)
58,108.98
Forward P/E
16.51
Dividend (Yield %)
--

Latest Developments

More

Eris Lifesciences Approves Buyback Of Shares Worth Up To 1 Bln Rupees

Eris Lifesciences To Consider Proposal Of Buyback Of Fully Paid-Up Equity Shares

India's Eris Lifesciences March Qtr Consol Net Profit Falls

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Eris Lifesciences Ltd

Eris Lifesciences Limited is an India-based company, which is engaged in manufacturing, marketing and selling of generics within the chronic and acute categories of the Indian Pharmaceutical Market. The Company operates within various areas through its seven focused divisions: Eris, Nikkos, Adura, Montana, Inspira, Victus, Eris Kinedex, Eterna, and Altiza. Its Eris division includes Atorsave 10, Atorsave 20, Decal, Enoxsave 0.6 and Metaloc XL100 products; its Nikkos division includes Alerfix, Erinac D, Ezeepam Plus 5, Zenpride OD and Nikotriol products; its Adura division includes Crevast 5, Glitaris M30, Metafort G1 CP and Olmin 10 products; its Montana division includes Meftaris, Calshine 60K Sachet, Hinder, Rabemon 20 and Vomisave Syrup products; its Inspira division includes Crevast F 5, Lnbeta 5 and Twichek products, and its Victus division includes Atorsave D80, Cyblex M 30 XR, Cyblex M 80, Cyblex M 60 XR and Cyblex MV 40.3 products.

Industry

Biotechnology & Drugs

Contact Info

7th Floor, Commerce House IV,,

Beside Shell Petrol Pump, 100 Feet Road,

+91.79.30451111

http://www.eris.co.in/

Executive Leadership

Amit Indubhushan Bakshi

Chairman of the Board, Managing Director

Sachin Shah

Chief Financial Officer

Milind Talegaonkar

Compliance Officer, Company Secretary

Inderjeet Singh Negi

Executive Director

Rajendrakumar Rambhai Patel

Head of Procurement

Key Stats

1.57 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, INR)

2018

8.6K

2019

9.8K

2020(E)

11.1K
EPS (INR)

2018

21.390

2019

21.130

2020(E)

25.593
Price To Earnings (TTM)
18.76
Price To Sales (TTM)
5.66
Price To Book (MRQ)
4.39
Price To Cash Flow (TTM)
16.37
Total Debt To Equity (MRQ)
1.28
LT Debt To Equity (MRQ)
0.63
Return on Investment (TTM)
23.18
Return on Equity (TTM)
20.24

Latest News

Latest News

BRIEF-India's Eris Lifesciences Dec-Qtr Consol Net Profit Rises

* DEC QUARTER CONSOL NET PROFIT 746 MILLION RUPEES VERSUS PROFIT 681 MILLION RUPEES YEAR AGO

BRIEF-India's Eris Lifesciences To Avail Loan Facility Worth 4 Bln Rupees From Axis Bank

* SAYS TO AVAIL TERM LOAN FACILITY WORTH 4 BILLION RUPEES FROM AXIS BANK LTD

BRIEF-RBI says foreign investment limit in Eris Lifesciences increased to 49 pct

* Investment under PIS in Eris Lifesciences Ltd by FII/FPI investment limit up from 24 percent to 49 percent; increase in NRI limit from 10 to 24 percent Source text: http://bit.ly/2w04o7W Further company coverage:

BRIEF-India's Eris Lifesciences June-qtr consol profit rises

* June quarter consol net profit 708.4 million rupees versus 624.4 million rupees year ago

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up